Whole genome sequencing reveals insights into hepatitis E virus genome diversity, and virus compartmentalization in chronic hepatitis E.
Hepatitis E Virus
High-throughput sequencing
Ribavirin resistance
Targeted enrichment
Virus diversity
Virus evolution
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
15
06
2023
revised:
24
08
2023
accepted:
11
09
2023
pmc-release:
01
11
2024
medline:
23
10
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
ppublish
Résumé
Hepatitis E virus (HEV) is a leading cause of acute hepatitis and can cause chronic infections in immunocompromised patients. Although HEV infections can be treated with ribavirin, antiviral efficacy is hampered by resistance mutations, normally detected by virus sequencing. High-throughput sequencing (HTS) allows for cost-effective complete viral genome sequencing. This enables the discovery and delineation of new subtypes, and revised the recognition of quasispecies and putative resistance mutations. However, HTS is challenged by factors including low viral load, sample degradation, high host background, and high viral diversity. We apply complete genome sequencing strategies for HEV, including a targeted enrichment approach. These approaches were used to investigate sequence diversity in HEV RNA-positive animal and human samples and intra-host diversity in a chronically infected patient. Here, we describe the identification of potential novel subtypes in a blood donation (genotype 3) and in an ancient livestock sample (genotype 7). In a chronically infected patient, we successfully investigated intra-host virus diversity, including the presence of ribavirin resistance mutations. Furthermore, we found convincing evidence for HEV compartmentalization, including the central nervous system, in this patient. Targeted enrichment of viral sequences enables the generation of complete genome sequences from a variety of difficult sample materials. Moreover, it enables the generation of greater sequence coverage allowing more advanced analyses. This is key for a better understanding of virus diversity. Investigation of existing ribavirin resistance, in the context of minorities or compartmentalization, may be critical in treatment strategies of HEV patients.
Sections du résumé
BACKGROUND
Hepatitis E virus (HEV) is a leading cause of acute hepatitis and can cause chronic infections in immunocompromised patients. Although HEV infections can be treated with ribavirin, antiviral efficacy is hampered by resistance mutations, normally detected by virus sequencing.
OBJECTIVES
High-throughput sequencing (HTS) allows for cost-effective complete viral genome sequencing. This enables the discovery and delineation of new subtypes, and revised the recognition of quasispecies and putative resistance mutations. However, HTS is challenged by factors including low viral load, sample degradation, high host background, and high viral diversity.
STUDY DESIGN
We apply complete genome sequencing strategies for HEV, including a targeted enrichment approach. These approaches were used to investigate sequence diversity in HEV RNA-positive animal and human samples and intra-host diversity in a chronically infected patient.
RESULTS
Here, we describe the identification of potential novel subtypes in a blood donation (genotype 3) and in an ancient livestock sample (genotype 7). In a chronically infected patient, we successfully investigated intra-host virus diversity, including the presence of ribavirin resistance mutations. Furthermore, we found convincing evidence for HEV compartmentalization, including the central nervous system, in this patient.
CONCLUSIONS
Targeted enrichment of viral sequences enables the generation of complete genome sequences from a variety of difficult sample materials. Moreover, it enables the generation of greater sequence coverage allowing more advanced analyses. This is key for a better understanding of virus diversity. Investigation of existing ribavirin resistance, in the context of minorities or compartmentalization, may be critical in treatment strategies of HEV patients.
Identifiants
pubmed: 37716229
pii: S1386-6532(23)00206-8
doi: 10.1016/j.jcv.2023.105583
pmc: PMC10643812
mid: NIHMS1933140
pii:
doi:
Substances chimiques
Ribavirin
49717AWG6K
Antiviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105583Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Arch Virol. 2015 Nov;160(11):2791-8
pubmed: 26303139
PLoS Pathog. 2016 Apr 01;12(4):e1005521
pubmed: 27035822
EBioMedicine. 2018 Oct;36:122-130
pubmed: 30190208
Gut. 2016 Oct;65(10):1733-43
pubmed: 27222534
Curr Opin Virol. 2018 Oct;32:80-87
pubmed: 30384328
Emerg Infect Dis. 2016 Jul;22(7):1249-52
pubmed: 27315454
Emerg Infect Dis. 2016 Dec;22(12):2219-2221
pubmed: 27869607
Epidemiol Infect. 2018 Sep;146(12):1533-1536
pubmed: 29792586
J Virol. 2006 Jun;80(12):5919-26
pubmed: 16731930
J Hepatol. 2017 Nov;67(5):925-932
pubmed: 28734938
Zoonoses Public Health. 2018 Feb;65(1):11-29
pubmed: 28944602
Hepatology. 2023 Dec 1;78(6):1882-1895
pubmed: 37334496
Sci Rep. 2022 Feb 2;12(1):1720
pubmed: 35110582
J Assoc Physicians India. 2018 Mar;66(3):92-3
pubmed: 30341882
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):559-63
pubmed: 1731327
Nat Rev Dis Primers. 2017 Nov 16;3:17086
pubmed: 29154369
Dis Aquat Organ. 2017 Feb 8;123(1):13-18
pubmed: 28177289
Transbound Emerg Dis. 2022 Mar;69(2):221-226
pubmed: 34850584
Open Forum Infect Dis. 2017 Jun 13;4(3):ofx121
pubmed: 28721353
J Gen Virol. 2020 Jul;101(7):692-698
pubmed: 32469300
Virus Evol. 2015 May 26;1(1):vev003
pubmed: 27774277
PLoS One. 2007 Dec 05;2(12):e1261
pubmed: 18060057
Euro Surveill. 2013 Apr 18;18(16):20461
pubmed: 23611031
Genome Res. 2015 Dec;25(12):1910-20
pubmed: 26395152
BMC Genomics. 2019 Feb 26;20(1):155
pubmed: 30808306
N Engl J Med. 2008 Feb 21;358(8):811-7
pubmed: 18287603
Hepatology. 2012 Apr;55(4):988-97
pubmed: 22121109
Liver Transpl. 2008 Apr;14(4):547-53
pubmed: 18383084
Virus Res. 2011 Oct;161(1):47-58
pubmed: 21345356
Emerg Infect Dis. 2012 Aug;18(8):1369-70
pubmed: 22840220
J Infect Dis. 2017 Apr 15;215(8):1197-1206
pubmed: 28199701
J Hepatol. 2022 Sep;77(3):870-872
pubmed: 35487383
J Infect. 2018 Sep;77(3):220-226
pubmed: 29966614
Microorganisms. 2021 Nov 05;9(11):
pubmed: 34835427
Clin Infect Dis. 2020 Aug 22;71(5):1204-1211
pubmed: 31793638
J Clin Virol. 2014 May;60(1):60-2
pubmed: 24583064
J Virol Methods. 2006 Jan;131(1):65-71
pubmed: 16125257
Emerg Infect Dis. 2014 Jun;20(6):1044-8
pubmed: 24856611
Emerg Infect Dis. 2013 Dec;19(12):2028-30
pubmed: 24274600